The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children

Asmaa Hachim[1], Haogao Gu[2], Otared Kavian[3], Mike YW Kwan[4], Wai-hung Chan[5], Yat Sun Yau[5], Susan S Chiu[6], Owen TY Tsang[7], David SC Hui[8], Fionn Ma[1], Eric HY Lau[9], Samuel MS Cheng[2], Leo LM Poon[1, 2], JS Malik Peiris[1, 2], Sophie A Valkenburg[1*^] and Niloufar Kavian[1, 10,11*].

Affiliation

[1]HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

[2]Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

[3]Department of Mathematics, Université de Versailles Saint-Quentin, Versailles, France

[4]Department of Paediatric and Adolescent Medicine, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.

[5]Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.

[6]Department of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.

[7]Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.

[8]Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China.

[9]WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

[10]Faculté de Médecine Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Service d'Immunologie Biologique, Paris, France.

[11]Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

*Contributed equally to this study

^corresponding author:

Sophie A Valkenburg

HKU Pasteur Research Pole

School of Public Health

The University of Hong Kong

sophiev@hku.hk

Short title: COVID-19 antibodies in children

Keywords: Antibody, COVID-19, asymptomatic, pediatric, IFN, accessory, structural, longitudinal

Author contributions

A.H. and N.K. performed the experiments and analysed the data. H.G., O.K. and E.H.Y.L performed specialist statistical analysis. M.Y.W.K, W.H.C, Y.S.Y, S.S.C, O.T.Y.T, D.S.C.H and S.M.S.C provided clinical samples, which F.M processed. A.H., L.L.M.P.,

J.S.M.P., S.A.V. and N.K. designed the study, interpreted results and wrote the manuscript.

Abstract

Background: Children are less clinically affected by SARS-CoV-2 infection than adults with the majority of cases being mild or asymptomatic and the differences in infection outcomes are poorly understood. The kinetics, magnitude and landscape of the antibody response may impact the clinical severity and serological diagnosis of COVID-19. Thus, a comprehensive investigation of the antibody landscape in children and adults is needed.

Methods: We tested 254 plasma from 122 children with symptomatic and asymptomatic SARS-CoV-2 infections in Hong Kong up to 206 days post symptom onset, including 146 longitudinal samples from 58 children. Adult COVID-19 patients and pre-pandemic controls were included for comparison. We assessed antibodies to a 14-wide panel of SARS-CoV-2 structural and accessory proteins by Luciferase Immunoprecipitation System (LIPS).

Findings: Children have lower levels of Spike and Nucleocapsid antibodies than adults, and their cumulative humoral response is more expanded to accessory proteins (NSP1 and Open Reading Frames (ORFs)). Sensitive serology using the three N, ORF3b, ORF8 antibodies can discriminate COVID-19 in children. Principal component analysis revealed distinct serological signatures in children and the highest contribution to variance were responses to non-structural proteins ORF3b, NSP1, ORF7a and ORF8. Longitudinal sampling revealed maintenance or increase of antibodies for at least 6 months, except for ORF7b antibodies which showed decline. It was interesting to note that children have higher antibody responses towards known IFN antagonists: ORF3b, ORF6 and ORF7a. The diversified SARS-CoV-2 antibody response in children may be an important factor in driving control of SARS-CoV-2 infection.

Introduction

The SARS-CoV-2 virus emerged in December 2019 and given the lack of pre-existing immunity has caused a pandemic. The spectrum of COVID-19 disease ranges from asymptomatic to lethal infection. It is now evident that the immune response plays a major role in the pathogenicity and outcome COVID-19[1]. Children are minimally affected clinically by SARS-CoV-2 and the morbidity and mortality observed in adults increases progressively with age, although the viral loads in the respiratory tract are reportedly comparable between children of all ages and adults[2]. The multisystem inflammatory syndrome (MIS-C) that appears in children after infection with SARS-CoV-2 is a rare exception (0.002% of cases) to the generally milder clinical disease observed[3]. Symptoms such as fever, cough, pneumonia and elevated C-reactive protein which are associated with disease severity, are less common in children[4]. The majority of children are asymptomatic and only a minority develop mild symptoms (most commonly fever, cough, pharyngitis, gastrointestinal symptoms and anosmia)[4], creating difficulties in identifying pediatric cases and in contact tracing. These observations are in contrast with other respiratory virus infections (respiratory syncytial virus (RSV), influenza virus) where children are affected more commonly and more severely compared to adults[5]. Recently, a small family case study by Tosif *et al*., indicated that children can mount an immune response with detectable antibodies to SARS-CoV-2 without preceding detectable viral load, therefore avoiding the development of a symptomatic SARS-CoV-2 infection[6]. The clinical differences observed in children and adults upon SARS-CoV-2 infection may be explained by several immune factors (amongst other clinical or physiological factors), such as pre-existing and cross-reactive immunity to common cold coronaviruses (CCC)[7]

99 with more recent exposure likely in children, immuno-senescence and inflammatory
100 state[8], innate immune responses, presence of auto-antibodies[9], and “trained immunity”
101 as a result of off-target effects of live attenuated vaccines for other infections[5,10].
102 Although a growing number of SARS-CoV-2 serology tests are currently in use worldwide
103 and are the basis of the SARS-CoV-2 infection rate data, there is an absence of
104 information on serological responses in children with RT-PCR confirmed SARS-CoV-2
105 infection. Large epidemiological studies report that children only represent 1-2% of all
106 SARS-CoV-2 cases[11,12] but this may be and underestimate because of differences in the
107 development of the antibody responses to SARS-CoV-2 in children and pandemic
108 response measures such as school closures. Serology is crucial for determining infection
109 attack rates in the population and for assessing the response to a future vaccine to curb
110 the global pandemic. Most serological tests available rely either on neutralizing antibodies
111 or on the detection of antibodies targeting the Spike (S) or the Nucleocapsid (N) proteins
112 of the virus[13]. We have previously demonstrated that antibodies that are directed against
113 non-structural proteins of the virus, namely ORF3b and ORF8, can be used for accurate
114 diagnosis of SARS-CoV-2 infection[14]. Whilst the cellular immune profile of children
115 appears comparable to adults in a small case study[6], there are no reports on the humoral
116 antibody landscape and kinetics in pediatric cases. There is a lack of information on the
117 SARS-CoV-2 antibody responses in adults or children to the virus accessory proteins, for
118 instance ORF3b, ORF6 and ORF7a, which have been reported to be potent interferon
119 antagonists that may play a role in immune evasion[15-17]. A finely tuned and balanced
120 antibody response may impact COVID-19 outcomes, and the breadth and magnitude of

121 the landscapes of antibody responses to non-structural proteins may indicate the extent
122 of virus replication and thus immune control.
123 In the present study, children and adults with SARS-CoV-2 RT-PCR confirmed infection
124 were used to study the antibody landscape to a comprehensive panel of 14 different
125 structural and accessory proteins by LIPS. We tested a population of 122 infected children
126 and 36 infected adults in Hong Kong, including 58 patients with longitudinal samples (2
127 to 4 time points, with a range 0 to 206 days post infection) to determine the longevity of
128 the antibody responses. Furthermore, due to intensive contact tracing and case-finding
129 measures in Hong Kong, asymptomatic cases with RT-PCR confirmed infections have
130 been identified and their antibody responses are also profiled. These samples were
131 collected between April to November 2020 and include predominantly the third wave of
132 infection cases in Hong Kong corresponding to the period of July to September 2020. Our
133 data reports to date, the most extensive data on the landscape and kinetics of antibody
134 responses in COVID-19 children.

135 **Results**

136 **SARS-CoV-2 infected children have lower levels of antibodies than adults to all**
137 **structural proteins, except E.**

138 We used the unbiased and quantitative LIPS platform to determine the antibody titres to
139 an extensive panel of 14 antigens from structural and non-structural SARS-CoV-2
140 proteins in plasma samples from a cohort of infected children, in comparison to adults
141 and controls in Hong Kong (Table 1).

142 Our first data set represents COVID-19 cases of mixed timepoints and symptoms to
143 determine the overall antibody landscapes in children (mean+/-stdev: 39±47 days, range:
144 0-206 days), adults (mean±stdev: 54±20 days, range: 24-123 days) and negative
145 controls. S and N antibodies are the most widely used antibodies in COVID-19 serology
146 testing worldwide. We therefore first determined the levels of antibodies to different S
147 sub-units by using 3 different S constructs in the LIPS assay: S1 which contains the RBD
148 domain, S2 and the S2' cleaved subunit (Figure 1). The levels of the two Spike antibodies,
149 S1 and S2' were markedly lower in children compared to the adult cohort ($p<0.0001$,
150 $p=0.0015$ and $p<0.0001$ respectively, Figure 1ac), whereas no difference was observed
151 for S2 antibodies (Figure 1b). Moreover, N antibodies were significantly elevated in the
152 pediatric COVID-19 cohort relative to negative controls (2.45e5±2.8e5 LU versus
153 4.15e4±1.5e4 LU ($p=0.0045$), but did not reach the levels observed in the COVID-19 adult
154 cohort that were almost half a log above (5.45e5±3.0e5 LU adult COVID-19 cohorts,
155 $p<0.0001$, Figure 1d).

156 We also assessed by LIPS antibodies to other structural proteins Matrix (M) and Envelope
157 (E), which are not widely measured in serology. As for S1, S2', and N, we found that M

158 antibody levels were lower in the COVID-19 children compared to the adult COVID cohort
159 ($p<0.0001$, Figure 1e) but were significantly higher that seen in controls. E antibodies
160 followed an inversed trend as they were significantly elevated in the pediatric COVID-19
161 cohort (Figure 1f) compared to both adult COVID-19 ($p=0.0006$) and negative controls
162 ($p<0.0001$).
163
164 **Increased breadth of accessory antigen targets in the pediatric COVID-19**
165 **population.**
166 We next investigated the levels of antibodies directed against the non-structural protein
167 1 (NSP1) and all the ORFs proteins of the virus. In line with our previous study[14], adults
168 with COVID-19 displayed elevated levels of NSP1, ORF3a, ORF3b, ORF7a, ORF7b, and
169 ORF8 antibodies compared to negative controls ($p<0.0001$, $p<0.0001$, $p<0.0001$, $p=0.05$,
170 $p=0.0009$, $p<0.0001$, Figure 2a-c and e-g). Again, no detectable levels of ORF6 and
171 ORF10 antibodies were detected in the adult COVID-19 population ($p=0.8691$ and
172 $p=0.999$ respectively, Figure 2d and 2h). We observed that the COVID-19 children cohort
173 displayed significantly lower levels of ORF3a, ORF7a, ORF7b antibodies than the adult
174 COVID-19 cohort ($p=0.0001$, $p<0.0001$ and $p<0.0001$ respectively, Figure 2b, e-f). The
175 magnitude of antibody responses to NSP1, ORF3b and ORF8 were comparable in the
176 pediatric COVID-19 and adult COVID-19 populations, and significantly elevated
177 compared to negative controls (Figure 2c and g).
178 Cumulative SARS-CoV-2 antibody responses from COVID-19 children and adults
179 populations were then compared as percentages of the total SARS-CoV-2 structural and
180 accessory antibody response. The anti-N antibodies substantially dominate the SARS-

181 CoV-2 humoral response detected by LIPS in both populations (Figure 2i-j), which is
182 consistent with our previous findings in the adult population[14]. Due to the
183 immunodominant effect of anti-N antibodies, we also performed analysis with or without
184 N, both of which were highly significant ($p<0.0001$ Supplemental Figure 1b-e).
185 Furthermore, representation of cumulative percentages of single specific antibodies to
186 the global SARS-CoV-2 antibody response shows that the amount of the response
187 towards the accessory proteins (NSP1 and ORFs) is increased over the response
188 towards the structural ones in the pediatric COVID-19 population versus the adult COVID-
189 19 population (8.81% versus 4.36% for the response to accessory proteins, $p=0.019$,
190 Figure 2j) despite no significant differences in total IgG levels in both populations
191 (Supplemental Figure 1a).
192

193 **Deciphering the SARS-CoV-2 antibody landscape differences in children and**
194 **adults using clusters of points and principal component analysis.**

195 A cluster of points depicts each individual sample in a more complete way than a single
196 statistical comparison, as it considers a combination of three (or more) different
197 parameters taken together and the relevant relations of these parameters. To decipher
198 the SARS-CoV-2 antibody landscape in children, we used relevant antibody
199 combinations to represent the COVID-19 pediatric samples in clusters of points along
200 with the negative and COVID-19 adult populations (Figure 3a-c and Supplemental figure
201 2).

202 First, the cluster representing the three antibodies to the S subunit antigens S1, S2', S2
203 confirmed that the pediatric population has a S antibody profile that is more closely
204 comparable to negative controls (Figure 3a) than an adult COVID-19 response by LIPS
205 (Figure 3b). Further cluster analysis of antibodies to S1, S2' with N, or other structural
206 proteins N, M, and E reveals that the COVID-19 children population appears to be quite
207 heterogeneous (Supplemental Figure 2a-b). Despite having a different profile than both
208 the adult COVID-19 and the negative populations, the pediatric population cannot be
209 clearly discriminated.

210 We then selected accessory protein antibodies as combinations to investigate the
211 relevance of under-utilized markers. ORF3b and ORF8 antibodies were selected, along
212 with N antibodies, as both were previously shown to discriminate accurately COVID-19
213 adults from negative controls[14]. The (N, ORF3b, ORF8) cluster of points can accurately
214 allow the positive discrimination of the pediatric COVID-19 cases from the negatives
215 (Figure 3c). Indeed, in the (N, ORF8; x, y) plane, the negative population is separated
216 from the adult and pediatric positive ones by two-segments of straight lines (equations of
217 830*log (N) +0.3843*ORF8=4801 and -350*log (N) +1.036*ORF8=790, with all positive
218 samples represented above or on these lines, and only one negative sample being above
219 these lines). Then, using the (ORF3b, ORF8; y, z) plane, again, two-segments of straight
220 lines (equations of 0.035*ORF3n+0.1334*ORF8=409.284 and
221 0.074*ORF3b+0.0437*ORF8=221.812) separate the negative samples from the adult
222 and pediatric positive ones. Therefore, the (N, ORF3b, ORF8) cluster reveals that the
223 pediatric COVID population resembles a COVID-19 adult population and can be
224 discriminated from negative pre-pandemic controls. Importantly, this is the only

225 combination that allowed us this discrimination, as other parameter combinations (e.g.
226 (N, S1, S2'), (N, E, M) in Supplemental Figure 2) and combinations of antibodies to
227 accessory proteins) were also tested and represented as clusters of points but did not
228 discriminate pediatric samples. These data cluster analysis show that the antibody
229 landscape of the COVID-19 children population is distinct from the adult one.

230 To test the hypothesis that the antibody landscape to structural and accessory viral
231 proteins drives the distinct profile of the pediatric population, we undertook a principal-
232 component analysis (PCA) of the 14 SARS-CoV-2 antibodies for the full data set (from
233 Figure 1 and 2). Dimension (principal component) 1 and 2 explained respectively 21%
234 and 15% of the total variances from all the 14 antibody types (Figure 3d-e). Accessory
235 proteins ORF3b, NSP1, ORF8, ORF3a, ORF7a, ORF6 and ORF10 had high correlation
236 values (Supplemental table 1), reflecting that antibodies to structural proteins do not
237 solely drive the principal component 1. Particularly, contributions of ORF3b, NSP1, ORF8,
238 ORF3a were the highest in Dimension 1 (Dim1, Figure 3de). Moreover, PCA showed that
239 ORF3b and ORF7a antibodies highly contributed to the differences seen in both
240 dimensions (Figure 3d) highlighting their importance in the serological response.

241 Strikingly, the PCA revealed that pediatirc COVID-19 antibody response was also
242 intermediate between COVID-19 adults and negatives (Figure 3f). Indeed, the normal-
243 probability representation of the 3 populations showed that only 18.9% of the pediatric
244 patients overlapped with the ellipse of the COVID-19 adults and only 3.54% overlapped
245 with the ellipse of the negatives (Figure 3f). Further analysis on gender, time-point,
246 symptoms and neutralization data (PRNT90) values reported that these were not

247 significant factors in discriminating the data (Supplemental Figure 3). Therefore, the
248 differences in the observed SARS-CoV-2 antibody responses is primarily explained by
249 the age and type of patients: pediatric COVID-19, adult COVID-19 or pre-pandemic
250 negative controls.

251

252 **No difference in antibody responses between symptomatic and asymptomatic**
253 **COVID-19**

254 To assess the potential effect of antibodies to structural and non-structural proteins of
255 SARS-CoV-2, we further stratified data (from Figure 1 and 2) into symptomatic
256 (mild/severe) and asymptomatic for both the adult and pediatric cohorts.
257 We found no differences in antibody responses between asymptomatic and mild COVID-
258 19 children for all 14 antigens. In adults, we observed the same trend excluding ORF3a
259 antibody levels which are higher for symptomatic patients ($p=0.0403$, Figure 4b). More
260 importantly N, M, ORF3a and ORF7b antibody levels in asymptomatic children versus
261 asymptomatic adults were not significantly different ($p=0.5673$, $p=0.2669$, $p=0.9185$ and
262 $p=0.0859$ respectively, Figure 4), whilst symptomatic adults had an upregulated antibody
263 response to these antigens compared to symptomatic children ($p<0.0001$ for all 4
264 antigens, Figure 4 and Supplemental Figure 4a).

265

266 **Antibody landscapes at early infection and long-term stability**

267 We previously observed that the SARS-CoV-2 antibody responses can vary in magnitude
268 and specificity in adults between acute and convalescent to memory time-points[14]. To

study the effect of time in the pediatric COVID-19 population, we stratified pediatric responses of all 254 samples (Figures 1 and 2) by early (<d14) versus later (≥d14) time-points (Figure 5). S2, N and ORF7a specific antibodies were significantly increased after day 14 post symptom onset. In contrast, ORF3b and ORF7b antibodies elicited a higher antibody response prior to day 14 (Figure 5b). Finally, responses to structural proteins S1, S2, M and E and accessory proteins NSP1, ORF3a, ORF6 and ORF8 were comparable before and after day 14 (Figure 5ab).

To further confirm the stability of SARS-CoV-2 specific antibodies we used 146 longitudinal paired samples of 58 pediatric patients that had either 2, 3 or 4 blood draws (Figure 6a). The time-frame of sampling ranged from 0 to 206 days post-symptom onset, with the majority of samples from <14 days (n=63), or long term memory samples after day 60 (n=58) (Figure 6b). Using a linear mixed effects model, we determined that antibody responses to structural proteins S1, S2, S2', M and E were stable over time, whereas N was significantly increased ($p<0.001$) (Figure 6c). Furthermore, antibodies towards non-structural proteins NSP1, ORF3a, ORF3b and ORF7a also significantly increased over time ($p<0.001$, $p=0.001$, $p=0.027$ and $p=0.002$ respectively), whilst ORF6, ORF8 and ORF10 were stable (Figure 6c). Only ORF7b antibody response significantly decayed longitudinally at a slow rate ($p<0.001$, Figure 6c). In order to determine whether the slope of each serological marker could inform the disease outcome we compared asymptomatic and symptomatic patients but no significant differences were found ($p>0.05$ for all) (Supplemental figure 4).

292

293 **A distinct antibody landscape may impact IFNα levels**

294 Severe COVID-19 disease is associated with low IFNα responses in adults which has
295 been linked to the type-I IFN down-regulation roles of ORF3b, ORF7a and ORF6[15-17].
296 Antibodies to these 3 proteins in a cluster of points (ORF3b, ORF7a, ORF6 as *x,y,z*),
297 show that children have a heterogenous humoral profile towards these 3 type-I IFN down-
298 regulators (Figure 7a). To assess the IFNα response a quantitative ELISA was conducted
299 on plasmas collected before day 7 in children (n=48) and adults (n=18) (Figure 7b). We
300 observed a significant decrease of acute IFNα levels in children compared to the adult
301 samples (p=0.0165, Figure 7b), with only 3 pediatric samples showing a detectable IFNα
302 level. To further investigate the antibody profiles with IFNα responses, the total antibody
303 response of these 3 IFNα producing children compared to the non-responder children
304 (n=45), we plotted the average antibody responses to all 14 antigens for each group
305 (Pediatric IFNα$^-$ versus Pediatric IFNα$^+$, average: Figure 7c, and individuals:
306 Supplemental figure 6). We found a significant difference in the antibody distribution in
307 the 3 IFNα producing children versus the IFNα non-producing children (IFNα$^+$ versus
308 IFNα$^-$, p<0.0001), with IFNα$^+$ children having increased ORF6, ORF7a and ORF3b
309 antibodies, and lower ORF8 and E antibody levels. Notably ORF6 antibody levels were
310 particularly higher in one IFNα$^+$ asymptomatic child with low viral loads (Figure 7d).

311

312 **Discussion**

313 Young children account for only a small percentage of reported and medically attended
314 COVID-19 infections[5], which is unlikely to be completely explained by reduced exposures
315 and school closures. This difference is likely contributed to by differences in host
316 responses between children and adults. We present herein the most comprehensive
317 study to date of the magnitude, specificity and duration of SARS-CoV-2 specific
318 antibodies in children.

319 While the understanding of immunity to COVID-19 is growing at a fast pace,
320 information on the pediatric population remains limited largely due to their asymptomatic
321 and mild illness compared to the adult population. Furthering our understanding of the
322 immune mechanisms that lead to this mild clinical presentation could represent new
323 alternative therapeutics, prevention methods or improved diagnostics. Our work enables
324 unique serological insights on the long-term response and asymptomatic infections as
325 Hong Kong's pandemic control strategy has intensive testing, contact tracing and isolation
326 of all COVID-19 cases including asymptomatic and mild cases with longitudinal follow up.
327 This has provided us the opportunity to investigate a cohort of children with both
328 symptomatic and asymptomatic children. We describe the antibody diversity between day
329 0 and day 206 post-symptom onset, and reveal major differences in the antigens targeted
330 by the humoral immune response of COVID-19 children compared to adults which may
331 indicate differences in viral protein propagation kinetics, pathogenesis and IFN immune
332 evasion.

333 Importantly, we report that the proportion of the antibody response targeting the
334 accessory proteins is significantly increased in children versus adults. Antibodies to the

335 N structural protein largely dominate the humoral immune response both in children and
336 adults, though the total magnitude of the N-specific antibodies in children is substantially
337 lower than adults. Visualization of N antibody levels in our cluster representations clearly
338 show that only half of the pediatric cases have comparable levels of these antibodies to
339 adults. Others have also reported a reduced magnitude of N antibodies in children and
340 they suggested that this observation could be related to a lower release of N proteins
341 related to lower replication in children[18]. On the contrary, our data show that children
342 produce antibodies to some accessory proteins (namely NSP1, ORF3b and ORF8) at
343 similar levels to adults, and to structural protein E in higher proportions than adults, the
344 latter notorious for high turnover due to its pivotal role in viral propagation (reviewed in[19]).
345 Therefore, these accessory proteins are not being released to a lesser extent in children
346 but may reflect different virus pathogenesis in children compared to adults. Viral loads
347 have been shown to be comparable in children and adults, which may reflect similar levels
348 of viral replication[2].
349 For the Spike subunits antibodies, the (S1, S2', S2) cluster reveals that the children
350 population resembles a negative pre-pandemic population and not a COVID-19 adult one.
351 A recent study describes a lower anti-S IgG, IgM, IgA in the pediatric population which
352 correlates with our findings [20]. One explanation on the clinical difference between children
353 and adults raise that the pre-existing immunity against seasonal human coronaviruses
354 (HCoVs) that cross-reacts with SARS-CoV-2 is higher in children, as they have a higher
355 infection rate of seasonal HCoVs than adults[21]. Individuals exposed and unexposed to
356 SARS-CoV-2 have cross-reactive antibodies against the proteins of SARS-CoV-2 and
357 seasonal HCoVs[22,23]. Moreover because circulating HCoVs have a higher homology to

358 SARS-CoV-2 structural proteins than non-structural proteins (if they exist)[24,25], we would
359 expect a higher cross-reactivity for structural proteins based on pre-existing immunity.
360 SARS-CoV-2 infection back-boosts antibodies against conserved epitopes, including the
361 relatively conserved fusion peptide of the Spike S2 subunit[22,23]. In our hands, COVID-19
362 children and adults had comparable levels of S2 antibodies, contrary to S1 and S2', which
363 shows a possible effect of pre-existing HCoVs immunity for more conserved domains of
364 S such as S2.
365 Our observations of lower Nucleocapsid and Spike antibodies in COVID-19 children may
366 indicate that there may be lower sensitivity of serological detection for SARS-CoV-2 when
367 using assays based on S and/or N alone, leading to an underestimation of SARS-CoV-2
368 exposed children. S antibodies have been reported in lower magnitude in the majority of
369 mild adult infections, with higher levels being produced in severe cases[26], which is
370 consistent with our data on low S antibody levels in children which were also
371 asymptomatic or mild clinical scores. Low antibody levels and low affinity have been
372 associated with Antibody Dependent Enhancement by facilitation of viral uptake by host
373 cells[27], however yet no definitive evidence of ADE for SARS-CoV-2 neither in adults nor
374 in children has been brought forward[28], but warrants further investigation.
375 The plane (ORF3b/ORF8) in the cluster of points (N, ORF3b, ORF8) reveals that children
376 samples have specific combinatory values of these two antibodies that is consistent with
377 adult populations, and that makes them distinguishable from the negatives. Similar to
378 NSP1, we report the proportion of all non-structural antibodies makes a greater
379 contribution of the SARS-CoV-2 response in children than in adults. The Principal
380 Component Analysis of our dataset confirmed further the importance of antibodies to

381 accessory proteins in characterising the pediatric samples. Whether these antibodies to
382 accessory proteins play a role in the virus infectivity or in the pathogenesis of the disease
383 and in the milder outcome of SARS-CoV-2 infection in children presents further questions
384 for investigations.
385 ORF3b, ORF7a and ORF6 proteins have been previously reported to play a role in cellular
386 type-1 IFN down-regulation[15-17]. The cluster representation of ORF3b, ORF7a and ORF6
387 antibodies shows a different pattern between adult and children population. Furthermore,
388 the PCA revealed that ORF7a and ORF3b contributed highly to component 1 and 2 (Dim1
389 and Dim2) which accounted for 21% and 15% of the variances observed respectively,
390 pointing to a potential pivotal role of these antigens. In all COVID-19 infected children or
391 adults tested at early timepoints of infection (< day 7), the majority did not elicit a
392 detectable IFNα response, in line with previous findings[30], but overall children IFNα
393 responses were significantly lower than the adult ones. Amongst the IFNα responders
394 and non-responders in children a different antibody landscape suggests possible
395 functions of these markers in counteracting viral IFN down-regulation, with ORF6
396 antibody responses doubled in IFNα^{+} children. Bastard *et al*., reported anti-type I
397 interferon auto-antibodies in a subset of severe COVID-19 patients[9]. Moreover, a recent
398 study has linked high levels of auto-immunity with COVID-19 severe cases in adults[31]. As
399 children are less predisposed to auto-immunity than adults[32], it is possible this contributes
400 to their milder clinical presentation along with the diversified antibody landscape observed
401 in our study.
402 We report in children diverse antibody profiles in early versus late samples and the
403 maintenance or increase of all antibodies to structural and accessory proteins, except

404 ORF7b antibodies, for at least 6 months post-infection. Many factors play a role in
405 antibody long-term persistence, such as antigen release, antigen presentation, induction
406 of a germinal centre reaction and a memory B cell pool[33]. Additional studies on viral
407 proteins release, their roles and their specific B cells are needed to fully understand the
408 antibody landscape in children.
409 Our cohort did not include any case of Multi-inflammatory System in Children (MIS-C).
410 Although one study reported that no distinct antibody response was observed between
411 MIS-C and mild or asymptomatic children[18], it only measured S and N antibodies.
412 Therefore it would be of interest to study the whole spectrum of antibodies in this
413 population and particularly those targeting accessory proteins. In our hands, symptomatic
414 children have significant differences in antibody levels versus symptomatic adults only for
415 selected antibodies (N, M, ORF3a and ORF7b) which suggests that these markers could
416 play a role in infection control or infectivity.
417 It is possible that the interest for antibodies to SARS-CoV-2 internal proteins will grow
418 with the rollout of sub-unit Spike only vaccines, in order to allow the distinction between
419 SARS-CoV-2 past exposure and vaccination in specific populations and to create an
420 estimated date of exposure given the unique rate of waning of different specificities. The
421 emergence of certain viral mutants such as the ORF8 truncations[34] or recent ORF3b
422 deletions[35] could modify the contributions of certain ORFs, their antibodies responses
423 could also be used for epidemiology studies on the insurgence of different strains of the
424 virus.
425 In conclusion, we report the description of a more diversified antibody landscape
426 in the COVID-19 children population compared to adults, with an increased and sustained

427 humoral response to all accessory proteins of the virus. This study of antibody spectrum
428 provides insights into the importance of the breadth of responses and how it differs
429 between children and adult that have diverse outcomes of infection, and could inform
430 improved SARS-CoV-2 diagnostics for the pediatric population.

431 **Methods**

432 **Patients and samples collection**

433 Our study enrolled a total of 122 children patients and 36 adult patients based on
434 recruitment of available patients with RT-PCR confirmed COVID-19 infection in Hong
435 Kong. We used a total of 254 COVID-19 children plasma samples including 146
436 longitudinal samples from 58 subjects with 2 to 4 sampling time points, and 119 early
437 time-points samples (< day 14). Samples were used from children (mean±stdev: 39±47
438 days, range: 0-206 days) and adults (mean±stdev: 54±20 days, range: 24-123 days), with
439 the sample day was defined as day post-symptom onset or RT-PCR confirmation for
440 asymptomatic cases through contact tracing or quarantine. For measurement of IFNα, an
441 extra set of 18 COVID-19 adult patients sampled prior to day 7 was used in comparison
442 to 48 samples that were collected prior to day 7 in the COVID-19 pediatric cohort. The
443 COVID-19 patient study was approved by the institutional review board of the respective
444 hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon Central /
445 Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West Cluster (UW
446 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories East Cluster
447 Clinical Research Ethics Committee (CREC 2020.229). All of patients provided informed
448 consent.

449 The negative control plasma samples used in this study were from Hong Kong
450 blood donors collected from June to August 2017 (prior to the emergence of COVID-19),
451 used a total of 33 plasma samples including negative pediatric samples (n=20) and
452 negative adult samples (n=13). The collection of negative control blood donors was
453 approved by the Institutional Review Board of The Hong Kong University and the Hong

454 Kong Island West Cluster of Hospitals (approval number: UW16-254). Plasma samples
455 were collected from heparinized blood. All samples from COVID-19 patients or negative
456 controls were heat-inactivated prior to experimental use at 56°C for 30 minutes. Details
457 on the sample cohort are presented in Table 1.
458
459 **SARS-CoV-2 cloning and (Ruc)-antigen expression**
460 Based on previous studies describing the structure of the SARS-CoV-2 genome[25,36], an
461 extensive panel of 14 proteins (S1, S2, S2', E, M, N, NSP1, ORF3a, 3b, 6, 7a, 7b, 8, 10)
462 was chosen for antibody testing by LIPS. Primers and cloning for the amplification of
463 SARS-CoV-2 proteins were as previously described[14]. Constructs with pREN2-Renilla
464 luciferase plasmid containing the SARS-CoV-2 antigen of interest were transfected into
465 Cos1 cells and prepared as previously described[14].
466
467 **Measurement of antibody responses using LIPS**
468 The LIPS assays were performed following the protocol of Burbelo *et al.,* with the following
469 modifications[36], as previously described[14]. Briefly, (Ruc)-antigen (at an equal
470 concentration for each antigen at 10^7 per well) and plasma (heat inactivated and diluted
471 1:100) were incubated for 2 hours with shaking at 800rpm. Ultralink protein A/G beads
472 (Thermo-Fisher) were added to the (Ruc)-antigen and serum mixture in a 96-deep-well
473 polypropylene microtiter plate and incubated for 2 hours with shaking at 800rpm. The
474 entire volume was then transferred into HTS plates (Millipore) and washed as previously
475 described. The plate was read using QUANTI-Luc Gold substrate (Invivogen) as per
476 manufacturer's instructions on a Wallac MicroBeta JET luminometer 1450 LSC &

477 Luminescence counter and its software for analysis (PerkinElmer). Experimental controls
478 include no plasma blank wells with (Ruc)-antigens and negative control serum from
479 healthy donors plasma collected prior to the COVID-19 pandemic. The background
480 corresponds to the LU signal from each Ruc-fusion antigen with protein A/G and substrate
481 with no plasma.
482

483 **Enzyme-linked immunosorbent assay**

484 Total IgG were measured in plasma samples using the Total human IgG ELISA kit
485 (Thermo-Fisher) at a final dilution of 1:500,000 according to manufacturer's instructions.
486 IFN-α was measured in plasma samples using the Human IFN-α Platinum ELISA kit
487 (Invitrogen) at a dilution of 1:5 according to manufacturer's instructions.

488

489 **Clusters of points**

490 The SARS-CoV-2 antibodies dataset has been treated through the free software
491 ConTeXt, with LuaMetaTeXengine (version 2020.05.18) developed by Hans Hagen
492 (http://www.pragma-ade.nl) which uses TeX, Metapost and Lua to obtain the 3D clusters
493 of points shown in Figure 3abc, Figure 7c and Supplemental Figure 2. For clarity, only the
494 first 144 COVID-19 pediatric samples of the dataset are represented in the clusters of
495 points, along with n=36 COVID-19 adult samples and n=28 negatives.
496 In the cluster (N, ORF3b, ORF8), the equations of the red lines are: (1) in the plane (N,
497 ORF8) :830*log (N) +0.3843*ORF8=4801 and -350*log (N) +1.036*ORF8=790, and (2)
498 in the plane (ORF3b, ORF8): 0.035*ORF3b+0.1334*ORF8=409.284 and

499 0.074*ORF3b+0.0437*ORF8=221.812. These straight lines allow the most accurate
500 discrimination between negative controls and positive adult populations.
501
502 **Principal component analysis**
503 The LU for 14 antigens were log-scale transformed (the negative and zero values in the
504 data set were replaced by 1) prior to PCA analysis. The missing values in the dataset
505 were estimated by a probabilistic model [37]. The probabilistic model is tolerant to amounts
506 of missing values between 10% to 15% which is fit for our data. The missing data was
507 estimated using pcaMethods (version 1.80.0)[38]. The completed data were standardized
508 (scaled) before input in standard PCA (using *FactoMineR* (version 2.4)[39].. The PCA
509 results were extracted and visualized using factoextra (version 1.0.7)[40].
510
511 **Statistics and Reproducibility**
512 GraphPad Prism version 8 software (San Diego, CA) was used for statistical analysis. All
513 experiments were repeated twice independently. Antibody levels are presented as the
514 individual responses and geometric mean +/- standard deviation (stdev). Ordinary one-
515 way ANOVA with Tukey's multiple comparison test were performed to compare the
516 pediatric, adult and negative populations in Figures 1 and 2, and the early and late
517 samples in Figure 5. For Figure 2j, percentages were calculated by dividing each mean
518 antibody value by the sum of the total antibody responses, and compared using a Chi-
519 square test between the "observed" (pediatric) versus "expected" (adult) distributions.
520 For Figure 6c and Supplementary figure 3, a linear mixed effects model was fitted to
521 account for correlated responses for the longitudinal samples dataset. Log_{10} LIPS was

522 used for the analysis (as dependent variable) to reduce the impact of extreme values/non-
523 normality. For Supplementary figure 1, the distributions showed in the pie-charts were
524 compared using a Chi-square test between the “observed” (pediatric) versus “expected”
525 (adult) distributions.
526
527 **Data availability statement**
528 The data that support the findings of this study are available from the corresponding
529 author upon request.
530

531 **Figure legends**

532 **Figure 1. Comparison of antibody responses to SARS-CoV-2 structural proteins in**
533 **children and in adults with COVID-19.** Antibodies against the SARS-CoV-2 structural
534 proteins Spike S1 subunit (S1) (a), Spike S2 subunit (b), Spike S2' subunit (c),
535 Nucleocapsid (N) (d), Membrane (M) (e), and Envelope (E) (f) were measured by LIPS
536 from samples from pediatrics COVID-19 (n=254) or adult patients (n=36), and negative
537 controls (n=33). Background no plasma values were subtracted. Experiments were
538 repeated twice. All data represents individual responses, and the mean +/- stdev. Two-
539 sided P values were calculated using the Mann-Whitney U test. * shows statistical
540 significance between COVID-19 patients versus negative controls. **p<0.01, ***p<0,001,
541 **** p<0,0001.

542

543 **Figure 2. Antibody responses to SARS-CoV-2 non-structural proteins and ORFs are**
544 **lower in magnitude in children than in adults with COVID-19 but represent globally**
545 **a higher proportion of the SARS-CoV-2 humoral response.** Antibodies against NSP1
546 (a) (in ORF1ab), and other ORFs (ORF3a (b), ORF3b (c), ORF6 (d), ORF7a (e), ORF7b
547 (f), ORF8 (g) and ORF10 (h)) were measured in pediatric (n=254) and adult (n=36)
548 COVID-19 cases and negative controls (n=33) by LIPS to cover all the ORFs of the virus.
549 (i) A heatmap comparing the mean titres (LU) for structural (N, S, S1, S2', S2, M, E) and
550 accessory proteins (NSP1, ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF10) responses
551 in the COVID-19 pediatric and adult populations and Negatives. (j) Percentages of single
552 antibody levels to SARS-CoV-2 antigens of the cumulative SARS-COV-2 antibody
553 response in COVID-19 children and adults for the 14 antigens. Experiments were

554 repeated twice. Two-sided P values were calculated using the Mann-Whitney U test. *
555 shows statistical significance between COVID-19 patients versus negative controls.
556 *p<0.05, **p<0.01, ***p<0.005, **** p<0,0001. Data in (a-h) represents the individual
557 responses and mean +/- stdev, data in (i) represents mean values (LU), data in (j)
558 represents percentages.
559
560 **Figure 3**. **Representation of the pediatric COVID-19 population as a cluster of points**
561 **for relevant antibody combinations and Principal Component Analysis (PCA)**. (a-
562 b). Cluster representation of S1, S2', S2 antibodies combination. (a) shows the pediatric
563 COVID-19 population versus the adult COVID-19 population, (b) shows the pediatric
564 COVID-19 population versus the negative population. (c) Cluster representation of N,
565 ORF3b, ORF8 antibodies combination, for the pediatric COVID-19 population versus the
566 adult COVID-19 population and the negative population. Patients are presented
567 according to their values of SARS-CoV-2 individual LIPS antibodies as (x, y, z) in the
568 space. Pediatric COVID-19 patients (n=144) are represented as red dots. COVID-19 adult
569 patients (n=36 in (a-b) and n=24 in (c)) are represented in blue. The negative population
570 (n=28) is represented in gray. (d-f) PCA of 14 antibodies analyzed in COVID-19 pediatric
571 patients. Dim1 explains 21% of the variation, while Dim2 explains 15% of the variation.
572 (d) Correlation circle and contributions. The scale of contributions is indicated (right). (e)
573 Contribution of variables on dimensions 1 and 2. The red dashed line on the graph above
574 indicates the expected average contribution. (f) Factorial plot of PCA on dimension 1 and
575 2. The plot is colored by sample types, the largest point in shape in each group is the

576 group mean point (circle is for Adult positives, triangle for Negatives and squares for
577 Pediatric positives).
578
579 **Figure 4**. **Asymptomatic and mildly symptomatic children do not display different**
580 **antibody landscapes.** Pediatric and adult samples were stratified according to the
581 symptom score of the patients (asymptomatic « asympto » (pediatric COVID-19 n=98,
582 adults COVID-19 n=9) versus symptomatic « sympto » (pediatric COVID-19 n=156,
583 adults COVID n=27)), data from Figure 1 and 2 were analyzed according to "asympto"
584 and "sympto". (a) Antibodies against the SARS-CoV-2 structural proteins S1, S2, S2', N,
585 E, and M by LIPS. (b) Antibodies against SARS-COV-2 NSP1 (in ORF1ab), and all other
586 ORFs (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8 and ORF10). Two-sided P values
587 were calculated using the Mann-Whitney U test. * shows statistical significance between
588 COVID-19 patients versus negative controls. *p<0.05, **p<0.01, ***p<0.005, ****
589 p<0,0001. All data represent individual responses and the mean +/- stdev.
590
591 **Figure 5**. **A unique antibody landscape is specific of early time-point samples (<**
592 **day 14).** Pediatric samples were stratified according to the time-point of collection, and
593 data from Figure 1 and 2 were analyzed according to acute (<day 14, n=119) and later
594 time-points (≥day 14, n=135). (a) Antibodies against the SARS-CoV-2 structural proteins
595 S1, S2, S2', N, E, and M by LIPS. (b) Antibodies against NSP1 (in ORF1ab), and all other
596 ORFs (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8 and ORF10). P values were
597 calculated using the student t test. * shows statistical significance between acute time-
598 point pediatric COVID-19 patients versus late time-point pediatric COVID-19 patients.

599 *p<0.05, **p<0.01, ***p<0.005, **** p<0,0001. All data represent individual responses and
600 the mean +/- stdev.
601
602 **Figure 6**. **Longitudinal stability of antibody responses for structural and non-**
603 **structural SARS-CoV-2 proteins in COVID-19 children.** (a) Number of longitudinal
604 patients with either 2, 3 or 4 blood draws from 58 pediatric COVID-19 cases. (b) Sample
605 collection time-line (days post infection). (c) A linear trend on log_{10} LIPS values was fitted
606 for longitudinal samples for S1, S2', N, M E, NSP1, ORF3a, ORF3b, ORF7a, ORF7b,
607 ORF8 (n=58 pediatric COVID-19 patients).
608

609 **Figure 7**. **IFN-α producing pediatric patients display a different landscape of**
610 **antibody response to SARS-CoV-2 accessory proteins**. (a) Cluster representation of
611 antibodies to the accessory proteins ORF3b, ORF7a, ORF6 (x, y, z) for the COVID-19
612 pediatric samples (red, n= 144) versus the COVID-19 adult samples (blue, n= 27). (b)
613 Plasma IFN-α concentrations (pg/ml) in pediatric (n=48) and adult COVID-19 cases
614 (n=18) early timepoint samples (< day 7). Data represents individual responses and the
615 mean +/- stdev. (c) Pie charts of the cumulative antibody responses to the relevant SARS-
616 CoV-2 structural and non-structural protein antigens (excluding N) in COVID-19 pediatric
617 cohort stratified (positive/negative) by their IFN-α responses. (d) Individual data for IFN-
618 $α^+$ pediatric cases viral loads by RT-PCR, ORF3, ORF6, and ORF7b LIPS LU. P values
619 were calculated using Chi-squared test between the mean of IFNα- pediatric COVID-19
620 patients (N=45) and the $IFNα^+$ (N=3). ns, p=0.0591 *p<0.05, **p<0.01, ***p<0.001, ****
621 p<0.0001.

Acknowledgements

The authors thank the patients and their families for their participation, and are grateful to the hospital staff, clinicians and nurses, particularly Karen YS Yui, for sample coordination. We thank Professor JT Wu, Dr Mahen RP Perera and Dr Kathy Leung for providing donor plasma controls. This study was partly supported by the Theme based Research Grants Scheme (T11-712/19-N), Health and Medical Research Fund (HMRF COVID-190115 and COVID-190126), National Institutes of Allergy and Infectious Diseases, National Institutes of Health (USA) (contract HHSN272201400006C).

Ethics declaration

The COVID-19 patient study was approved by the institutional review board of the respective hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon Central / Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West Cluster (UW 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (CREC 2020.229). All of patients provided informed consent. The collection of plasma from blood donors serving as controls was approved by Institutional Review Board of The Hong Kong University and the Hong Kong Island West Cluster (UW16-254).

Competing interests

A Hachim, N Kavian, LLM Poon, JSM Peiris and SA Valkenburg have filed an IDF (US 63/016,898) for the use of ORF8 and ORF3b as diagnostics of SARS-CoV-2 infection.

645 **References**

646 1. Vabret, N.*, et al.* Immunology of COVID-19: Current State of the Science. *Immunity*
647 **52**, 910-941 (2020).
648 2. Jones T.C. , M.B., Veith T. , Guido Biele, Marta Zuchowski, Jörg Hoffmann, Angela
649 Stein, Anke Edelmann, Victor Max Corman, Christian Drosten. An analysis of
650 SARS-CoV-2 viral load by patient age. *medRxiv* (2020).
651 3. Valverde, I.*, et al.* Acute Cardiovascular Manifestations in 286 Children with
652 Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in
653 Europe. *Circulation* (2020).
654 4. Qiu, H.*, et al.* Clinical and epidemiological features of 36 children with coronavirus
655 disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.
656 *Lancet Infect Dis* **20**, 689-696 (2020).
657 5. Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review
658 of the proposed mechanisms underlying the age-related difference in severity of
659 SARS-CoV-2 infections. *Arch Dis Child* (2020).
660 6. Tosif, S.*, et al.* Immune responses to SARS-CoV-2 in three children of parents with
661 symptomatic COVID-19. *Nat Commun* **11**, 5703 (2020).
662 7. Gorse, G.J., Donovan, M.M. & Patel, G.B. Antibodies to coronaviruses are higher
663 in older compared with younger adults and binding antibodies are more sensitive
664 than neutralizing antibodies in identifying coronavirus-associated illnesses. *J Med*
665 *Virol* **92**, 512-517 (2020).
666 8. Freeman, T.L. & Swartz, T.H. Targeting the NLRP3 Inflammasome in Severe
667 COVID-19. *Front Immunol* **11**, 1518 (2020).
668 9. Bastard, P.*, et al.* Autoantibodies against type I IFNs in patients with life-
669 threatening COVID-19. *Science* **370**(2020).
670 10. Netea, M.G.*, et al.* Trained Immunity: a Tool for Reducing Susceptibility to and the
671 Severity of SARS-CoV-2 Infection. *Cell* **181**, 969-977 (2020).
672 11. Parri, N., Lenge, M., Buonsenso, D. & Coronavirus Infection in Pediatric
673 Emergency Departments Research, G. Children with Covid-19 in Pediatric
674 Emergency Departments in Italy. *N Engl J Med* **383**, 187-190 (2020).
675 12. Wu, Z. & McGoogan, J.M. Characteristics of and Important Lessons From the
676 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report
677 of 72314 Cases From the Chinese Center for Disease Control and Prevention.
678 *JAMA* **323**, 1239-1242 (2020).
679 13. Rikhtegaran Tehrani, Z.*, et al.* Performance of nucleocapsid and spike-based
680 SARS-CoV-2 serologic assays. *PLoS One* **15**, e0237828 (2020).
681 14. Hachim, A.*, et al.* ORF8 and ORF3b antibodies are accurate serological markers
682 of early and late SARS-CoV-2 infection. *Nat Immunol* **21**, 1293-1301 (2020).
683 15. Martin-Sancho, L.*, et al.* Functional Landscape of SARS-CoV-2 Cellular
684 Restriction. *bioRxiv* (2020).
685 16. Konno, Y.*, et al.* SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose
686 Activity Is Increased by a Naturally Occurring Elongation Variant. *Cell Rep* **32**,
687 108185 (2020).
688 17. Yuen, C.K.*, et al.* SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent
689 interferon antagonists. *Emerg Microbes Infect* **9**, 1418-1428 (2020).

690 18. Weisberg, S.P.*, et al.* Distinct antibody responses to SARS-CoV-2 in children and
691 adults across the COVID-19 clinical spectrum. *Nat Immunol* (2020).
692 19. Schoeman, D. & Fielding, B.C. Is There a Link Between the Pathogenic Human
693 Coronavirus Envelope Protein and Immunopathology? A Review of the Literature.
694 *Front Microbiol* **11**, 2086 (2020).
695 20. Weisberg, S.P.*, et al.* Distinct antibody responses to SARS-CoV-2 in children and
696 adults across the COVID-19 clinical spectrum. *Nat Immunol* **22**, 25-31 (2021).
697 21. Monto, A.S.*, et al.* Coronavirus Occurrence and Transmission Over 8 Years in the
698 HIVE Cohort of Households in Michigan. *J Infect Dis* **222**, 9-16 (2020).
699 22. Shrock, E.*, et al.* Viral epitope profiling of COVID-19 patients reveals cross-
700 reactivity and correlates of severity. *Science* **370**(2020).
701 23. Ng, K.W.*, et al.* Preexisting and de novo humoral immunity to SARS-CoV-2 in
702 humans. *Science* (2020).
703 24. Edridge, A.W.D.*, et al.* Seasonal coronavirus protective immunity is short-lasting.
704 *Nat Med* **26**, 1691-1693 (2020).
705 25. Chan, J.F.*, et al.* Genomic characterization of the 2019 novel human-pathogenic
706 coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.
707 *Emerg Microbes Infect* **9**, 221-236 (2020).
708 26. Haddad Natalie S , N.D.C., Kuruvilla Merin E, Morrison-Porter Andrea, Fabliha
709 Anam, Kevin S Cashman, Richard P Ramonell, Shuya Kyu, Ankur Singh Saini,
710 Monica Cabrera-Mora, Andrew Derrico, David Alter, John D Roback, Michael
711 Horwath, James B O'Keefe, Henry M Wu, An-Kwok Ian Wong, Alexandra W
712 Dretler, Ria Gripaldo, Andrea N Lane, Hao Wu, Saeyun Lee, Mindy Hernandez,
713 Vanessa Engineer, John Varghese, Sang Le, Iñaki Sanz, John L Daiss, F Eun-
714 Hyung Lee. Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early
715 COVID-19 Infection. *bioRxiv* (2020).
716 27. Katzelnick, L.C.*, et al.* Antibody-dependent enhancement of severe dengue
717 disease in humans. *Science* **358**, 929-932 (2017).
718 28. Guthmiller, J.J., Wilson P. C. Remembering seasonal coronaviruses. *Science* **370**,
719 1272-1273 (2020).
720 29. Le Bert, N.*, et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and
721 SARS, and uninfected controls. *Nature* **584**, 457-462 (2020).
722 30. Galani, I.E.*, et al.* Untuned antiviral immunity in COVID-19 revealed by temporal
723 type I/III interferon patterns and flu comparison. *Nat Immunol* (2020).
724 31. Wang, E.Y., Mao, T., Klein, J. , Dai, Y. , Huck, J. D., Liu, F., Zheng, N. S., Ting
725 Zhou, Benjamin Israelow, Patrick Wong, Carolina Lucas, Julio Silva,*, et al.* Diverse
726 Functional Autoantibodies in Patients with COVID-19. *MedRXiv* (2020).
727 32. Glowinska-Olszewska, B.*, et al.* Increasing Co-occurrence of Additional
728 Autoimmune Disorders at Diabetes Type 1 Onset Among Children and
729 Adolescents Diagnosed in Years 2010-2018-Single-Center Study. *Front*
730 *Endocrinol (Lausanne)* **11**, 476 (2020).
731 33. Rodda, L.B.*, et al.* Functional SARS-CoV-2-Specific Immune Memory Persists
732 after Mild COVID-19. *Cell* (2020).
733 34. Young, B.E.*, et al.* Effects of a major deletion in the SARS-CoV-2 genome on the
734 severity of infection and the inflammatory response: an observational cohort study.
735 *Lancet* **396**, 603-611 (2020).

736 35. Lam, J.Y., *et al.* Loss of orf3b in the circulating SARS-CoV-2 strains. *Emerg*
737 *Microbes Infect*, 1-678 (2020).
738 36. Wu, F., *et al.* A new coronavirus associated with human respiratory disease in
739 China. *Nature* **579**, 265-269 (2020).
740 37. Burbelo, P.D., Ching, K.H., Klimavicz, C.M. & Iadarola, M.J. Antibody profiling by
741 Luciferase Immunoprecipitation Systems (LIPS). *J Vis Exp (JoVE)* **32**(2009).
742 38. Roweis, S. EM Algorithms for PCA and Sensible PCA. (1997).
743 39. Stacklies W., Redestig H., Scholz M., Walther D. & J., S. Methods – a
744 Bioconductor package providing PCA methods for incomplete data.
745 (Bioinformatics, 2007).
746 https://bioconductor.org/packages/release/bioc/html/pcaMethods.html.
747 40. Lê, S., Josse, J. & Husson, F. FactoMineR: An R Package for Multivariate
748 Analysis. (2008). http://www.jstatsoft.org/v25/i01/
749 41. R project. https://cran.rproject.org/web/packages/factoextra/index.html

750

Table 1. Subject cohorts details

		Pediatric COVID-19		***Adults COVID-19***		***Negative***	
		N (%)		**N (%)**		**N (%)**	
Patients	*Samples*	254		36		33	
	Individuals	122		36		33	
Symptoms	*Asymptomatic*	44 (36%)		9 (25%)		-	
	Mild/Severe	78/0		25/1		-	
Age		Mean±stdev	10.8 ± 4.9 years	Mean±stdev	34 ± 17.1 years	Mean±stdev	29.3 ± 16.3 years
		0-8 years	45 (37%)	Median	31	Adults (N=13)	30 - 65
		8-12 years	33 (27%)	Min	18	Pediatrics (N=20)	11 - 18
		12-18 years	44 (36%)	Max	71		
Gender	*Female*	49 (40%)		10 (28%)		17 (51%)	
	Male	73 (60%)		26 (72%)		16 (49%)	


Spike Subunits
Other Structural proteins
a
S1 LIPS (LU)
8000
6000
4000
2000
0
****
***
b
S2 LIPS (LU)
15000
10000
5000
0
c
S2' LIPS (LU)
4000
2000
0
****
****
d
N LIPS (LU)
10^7
10^6
10^5
10^4
***
****
****
e
M LIPS (LU)
15000
10000
5000
0
**
****
f
E LIPS (LU)
20000
15000
10000
5000
0
***
****
Pediatrics COVID
Adults COVID
Negatives

Figure 1.



	Pediatric COVID-19	Adults COVID-19
Structural	91.19%	95.64%
Accessory	8.81%	4.36%

Figure 2.


a
S2 (2.5 × 10³ LU)
S1 (2.5 × 10³ LU)
S2' (2.5 × 10³ LU)
S2' (2.5 × 10³ LU)
Pediatric Covid-19
Adult Covid-19
b
S2 (2.5 × 10³ LU)
S1 (2.5 × 10³ LU)
S2' (2.5 × 10³ LU)
S2' (2.5 × 10³ LU)
Pediatric Covid-19
Negatives
c
ORF8 (2.5 × 10³ LU)
log(10⁻⁴N) (LU)
ORF3b (2.5 × 10³ LU)
ORF3b (2.5 × 10³ LU)
Pediatric Covid-19
Adult Covid-19
Negatives
d
Variables – PCA
S1
ORF10
ORF7b
ORF7a
ORF3b
ORF6
M
S2
S2'
N
ORF3a
ORF8
NSP1
E
contrib
Dim1 (21%)
Dim2 (15%)
e
Individuals – PCA
Groups
Adults positives
Negatives
Pediatric positives
Dim1 (21%)
Dim2 (15%)
f
Contribution of variables to Dim−1
Contributions (%)
ORF3b
NSP1
ORF8
ORF3a
N
ORF7a
S2
ORF6
ORF10
E
S2'
M
S1
ORF7b
Contribution of variables to Dim−2
Contributions (%)
S1
ORF10
ORF7b
ORF7a
E
ORF3b
M
S2
ORF6
S2'
NSP1
ORF8
ORF3a
N


Structural proteins
Non-structural proteins
a
b
S1 LIPS (LU)
S2 LIPS (LU)
S2' LIPS (LU)
N LIPS (LU)
M LIPS (LU)
E LIPS (LU)
NSP1 LIPS (LU)
ORF3a LIPS (LU)
ORF3b LIPS (LU)
ORF6 LIPS (LU)
ORF7a LIPS (LU)
ORF7b LIPS (LU)
ORF8 LIPS (LU)
ORF10 LIPS (LU)
Asympto pediatrics
Sympto pediatrics
Asympto adults
sympto adults
ns
*
**
***
****

Figure 4.


a
Structural proteins
b
Non-structural proteins
S1 LIPS (LU)
S2 LIPS (LU)
S2' LIPS (LU)
N LIPS (LU)
E LIPS (LU)
M LIPS (LU)
NSP1 LIPS (LU)
ORF3a LIPS (LU)
ORF3b LIPS (LU)
ORF6 LIPS (LU)
ORF7a LIPS (LU)
ORF7b LIPS (LU)
ORF8 LIPS (LU)
ORF10 LIPS (LU)
d<14
D>14
*
**
***
****

Figure 5.


a
Amount of blood draws
4
3
2
3
20
35
0
10
20
30
40
number of patients
b
0
30
60
90
120
150
180
210
240
time (days)
0-14 days (n=63)
15-28 days (n=10)
29-60 days (n=15)
61-120 days (n=42)
121-180 days (n=11)
181-240 days (n=5)
c
S1, log10 LIPS
stable, ns (p=0.892)
S2', log10 LIPS
stable, ns (p=0.811)
N, log10 LIPS
increase, p<0.001
M, log10 LIPS
stable, ns (p=0.502)
E, log10 LIPS
stable, ns (p=0.246)
NSP1, log10 LIPS
increase, p<0.001
ORF3a, log10 LIPS
increase, p=0.001
ORF3b, log10 LIPS
increase, p=0.027
ORF7a, log10 LIPS
increase, p=0.002
ORF7b, log10 LIPS
decrease, p<0.001
ORF8, log10 LIPS
stable, p=0.463
onset day

Figure 6.


a
ORF6 (2.5 × 10³ LU)
ORF3b (2.5 × 10³ LU)
ORF7a (2.5 × 10³ LU)
ORF7a (2.5 × 10³ LU)
Pediatric Covid-19
Pediatric Covid-19
Adult Covid-19
b
plasmatic IFNα (pg/mL)
*
pediatrics COVID
Adults COVID
c
Pediatrics IFN+
Pediatrics IFN-
IFN+ IFN-
S1 1680 - 1909 (LU)
S2' 1236 - 1647 (LU)
S2 2410 - 1912 (LU)
M 2980 - 2987 (LU)
E 4224 - 3236 (LU)
NSP1 2699 - 2929 (LU)
ORF3a 3187 - 2200 (LU)
ORF3b 2623 - 2929 (LU)
ORF6 1669 - 3732 (LU)
ORF7a 1859 - 2140 (LU)
ORF7b 3677 - 3984 (LU)
ORF8 4277 - 3357 (LU)
ORF10 2213 - 2687 (LU)
d
ORF3b
ORF6
ORF7a
IFN+ Asympto
IFN+ Sympto A
IFN+ Sympto B
viral load